Biocompatible nanoadhesive offers hope for safer corneal transplants, reducing inflammation and infection risks
A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...
Active Biotech AB: Active Biotech's patent for laquinimod in eye disorders granted in the US
Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...
C&EN19d
177 Lu-Labeled Heterodimeric Agent with High Stability Targeting Neovascularization for Tumor Radioligand Therapy
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Hubei Province Key Laboratory of Molecular Imaging, Wuhan ...
BioWorld25d
CREB inhibitor successfully prevents corneal neovascularization
Corneal neovascularization (CNV) occurs when abnormal blood vessels grow into the cornea in response to ischemic or hypoxic conditions caused by infections, inflammation or chemical injuries. CREB ...
Medscape1mon
Management of Choroidal Neovascularization in Myopic Macular Degeneration
Photodynamic therapy with verteporfin of CNV represents an advancement in the treatment of myopic macular degeneration complicated by CNV. The aim of PDT is to treat CNV, especially located into ...
Healio1mon
Management of macular telangiectasia type 2 may be near
Once diagnosed, patients should be followed and monitored for development of subretinal neovascularization, known as proliferative MacTel. Subretinal neovascularization can result in significant ...